Microglia engineering and replacement to treat brain disease

The ReplaceMi project aims to develop a translatable strategy for replacing dysfunctional microglia with healthy progenitors to treat neurodegenerative diseases through innovative technologies.

Subsidie
€ 2.000.000
2023

Projectdetails

Introduction

Microglia are highly versatile brain resident cells that offer tremendous therapeutic opportunities. They are instrumental for maintaining healthy brain physiology and act as the primary modulators of neuroinflammation and disease.

Importance of Microglia

Microglial dysfunction has been convincingly linked to a myriad of neurological disorders, making these cells a prime target for therapeutic intervention. Remarkably, microglia are embryo-derived cells that self-maintain for life, with negligible replacement by the bone marrow. This astonishing self-renewal capacity offers a unique opportunity for cell therapy.

Therapeutic Potential

The ability to replace dysfunctional microglia with healthy or genetically enhanced counterparts may transform the way we treat brain disease. However, challenges arise in replacing a cell that is so adept at self-renewal in a tissue that is shielded from the periphery. Currently, there are no translatable approaches for the specific replacement of microglia. Furthermore, bone marrow progenitors are unable to adopt the embryonic microglial phenotype.

Research Objectives

By building on our unpublished observations and developing innovative technologies, I aim to lay the foundation for microglial replacement therapy. We intend to develop an original and translatable strategy for the specific and near-complete replacement of embryonic microglia with adoptively transferred progenitors.

Methodology

Next, by combining iPSC differentiation with genetic barcoding, single-cell analysis, and in vivo screening, we aim to identify progenitors that efficiently traffic to the brain and engraft as bona fide microglia.

Future Directions

Moreover, we will investigate how we can transform microglia into local protein production factories, as a potential basis to treat neurodegenerative diseases. Finally, we will set up in vivo pooled CRISPR screens to identify the gene networks that can modulate and positively enhance microglial disease responses.

Conclusion

ReplaceMi has the potential to result in a new and eagerly awaited breakthrough in treating brain disease.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.000.000
Totale projectbegroting€ 2.000.000

Tijdlijn

Startdatum1-8-2023
Einddatum31-7-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • VRIJE UNIVERSITEIT BRUSSELpenvoerder

Land(en)

Belgium

Vergelijkbare projecten binnen European Research Council

ERC Advanced...

A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic Diseases

Develop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment.

€ 2.495.250
ERC Advanced...

Microglia As conTroller of braIn metaboLism During Aging

This project aims to investigate how microglia, via the Trem2 gene, influence hypothalamic metabolism and energy homeostasis, with potential implications for treating immunometabolic dysfunction.

€ 2.500.000
ERC Starting...

Deciphering the microglia-neuron interactions in human Alzheimer's disease

This project aims to elucidate how human microglia contribute to neuronal toxicity in Alzheimer's disease using a pioneering xenograft model to explore their interactions and secretome.

€ 1.500.000
ERC Starting...

Dissection of Microglial State Biology in Brain Repair

This project aims to elucidate the dynamics and functions of microglial states during brain repair using a spatiotemporal atlas and novel molecular tools to enhance understanding of neuroinflammation.

€ 1.684.803
ERC Proof of...

TREM2 MICROglia ENGENEering for treating dementiaS (TREM2MICROENGINES)

TREM2MICROENGINES aims to restore TREM2 expression in microglia of Alzheimer's and Nasu–Hakola disease patients to enhance neuroinflammation response and reduce amyloid-β accumulation.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION

REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.

€ 2.943.233
EIC Transition

Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS

TREM2MEDS aims to transition a novel gene therapy for Alzheimer’s and Nasu-Hakola Diseases from preclinical validation to a Phase I clinical trial, targeting TREM2 dysfunction in microglia.

€ 2.499.721
EIC Pathfinder

AI-powered platform for autologous iPSC manufacturing

The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.

€ 3.999.225
EIC Pathfinder

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

€ 3.644.418
EIC Pathfinder

Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease

The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.

€ 2.992.203